235 related articles for article (PubMed ID: 16378743)
1. Childhood ataxia with CNS hypomyelination/vanishing white matter disease--a common leukodystrophy caused by abnormal control of protein synthesis.
Schiffmann R; Elroy-Stein O
Mol Genet Metab; 2006 May; 88(1):7-15. PubMed ID: 16378743
[TBL] [Abstract][Full Text] [Related]
2. Mutations causing childhood ataxia with central nervous system hypomyelination reduce eukaryotic initiation factor 2B complex formation and activity.
Richardson JP; Mohammad SS; Pavitt GD
Mol Cell Biol; 2004 Mar; 24(6):2352-63. PubMed ID: 14993275
[TBL] [Abstract][Full Text] [Related]
3. The large spectrum of eIF2B-related diseases.
Fogli A; Boespflug-Tanguy O
Biochem Soc Trans; 2006 Feb; 34(Pt 1):22-9. PubMed ID: 16246171
[TBL] [Abstract][Full Text] [Related]
4. [CACH/VWM syndrome and leucodystrophies related to EIF2B mutations].
Labauge P; Fogli A; Niel F; Rodriguez D; Boespflug-Tanguy O
Rev Neurol (Paris); 2007 Sep; 163(8-9):793-9. PubMed ID: 17878805
[TBL] [Abstract][Full Text] [Related]
5. Leukoencephalopathy with vanishing white matter due to homozygous EIF2B2 gene mutation. First Polish cases.
Mierzewska H; van der Knaap MS; Scheper GC; Jurkiewicz E; Schmidt-Sidor B; Szymańska K
Folia Neuropathol; 2006; 44(2):144-8. PubMed ID: 16823698
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of mutations for the diagnosis of vanishing white matter disease.
Scali O; Di Perri C; Federico A
Neurol Sci; 2006 Sep; 27(4):271-7. PubMed ID: 16998732
[TBL] [Abstract][Full Text] [Related]
7. Eukaryotic initiation factor 2B (eIF2B) GEF activity as a diagnostic tool for EIF2B-related disorders.
Horzinski L; Huyghe A; Cardoso MC; Gonthier C; Ouchchane L; Schiffmann R; Blanc P; Boespflug-Tanguy O; Fogli A
PLoS One; 2009 Dec; 4(12):e8318. PubMed ID: 20016818
[TBL] [Abstract][Full Text] [Related]
8. Intra-familial phenotypic heterogeneity in adult onset vanishing white matter disease.
Damon-Perriere N; Menegon P; Olivier A; Boespflug-Tanguy O; Niel F; Creveaux I; Dousset V; Brochet B; Goizet C
Clin Neurol Neurosurg; 2008 Dec; 110(10):1068-71. PubMed ID: 18845387
[TBL] [Abstract][Full Text] [Related]
9. Vanishing white matter disease.
van der Knaap MS; Pronk JC; Scheper GC
Lancet Neurol; 2006 May; 5(5):413-23. PubMed ID: 16632312
[TBL] [Abstract][Full Text] [Related]
10. Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patients.
Kantor L; Harding HP; Ron D; Schiffmann R; Kaneski CR; Kimball SR; Elroy-Stein O
Hum Genet; 2005 Oct; 118(1):99-106. PubMed ID: 16041584
[TBL] [Abstract][Full Text] [Related]
11. A Japanese girl with an early-infantile onset vanishing white matter disease resembling Cree leukoencephalopathy.
Takano K; Tsuyusaki Y; Sato M; Takagi M; Anzai R; Okuda M; Iai M; Yamashita S; Okabe T; Aida N; Tsurusaki Y; Saitsu H; Matsumoto N; Osaka H
Brain Dev; 2015 Jun; 37(6):638-42. PubMed ID: 25457085
[TBL] [Abstract][Full Text] [Related]
12. Infantile onset Vanishing White Matter disease associated with a novel EIF2B5 variant, remarkably long life span, severe epilepsy, and hypopituitarism.
Woody AL; Hsieh DT; McIver HK; Thomas LP; Rohena L
Am J Med Genet A; 2015 Apr; 167A(4):826-30. PubMed ID: 25758335
[TBL] [Abstract][Full Text] [Related]
13. Dominant form of vanishing white matter-like leukoencephalopathy.
Labauge P; Fogli A; Castelnovo G; Le Bayon A; Horzinski L; Nicoli F; Cozzone P; Pagès M; Briere C; Marty-Double C; Delhaume O; Gelot A; Boespflug-Tanguy O; Rodriguez D
Ann Neurol; 2005 Oct; 58(4):634-9. PubMed ID: 16047349
[TBL] [Abstract][Full Text] [Related]
14. A yeast purification system for human translation initiation factors eIF2 and eIF2Bε and their use in the diagnosis of CACH/VWM disease.
de Almeida RA; Fogli A; Gaillard M; Scheper GC; Boesflug-Tanguy O; Pavitt GD
PLoS One; 2013; 8(1):e53958. PubMed ID: 23335982
[TBL] [Abstract][Full Text] [Related]
15. [Natural history of adult-onset eIF2B-related disorders: a multicentric survey of 24 cases].
Carra-Dalliere C; Horzinski L; Ayrignac X; Vukusic S; Rodriguez D; Mauguiere F; Peter L; Goizet C; Bouhour F; Denier C; Confavreux C; Obadia M; Blanc F; de Seze J; Sedel F; Guennoc AM; Sartori E; Laplaud D; Antoine JC; Fogli A; Boespflug-Tanguy O; Labauge P
Rev Neurol (Paris); 2011 Nov; 167(11):802-11. PubMed ID: 21676421
[TBL] [Abstract][Full Text] [Related]
16. The effect of genotype on the natural history of eIF2B-related leukodystrophies.
Fogli A; Schiffmann R; Bertini E; Ughetto S; Combes P; Eymard-Pierre E; Kaneski CR; Pineda M; Troncoso M; Uziel G; Surtees R; Pugin D; Chaunu MP; Rodriguez D; Boespflug-Tanguy O
Neurology; 2004 May; 62(9):1509-17. PubMed ID: 15136673
[TBL] [Abstract][Full Text] [Related]
17. [Eukaryotic translation initiation factor 2B and leukoencephalopathy with vanishing white matter].
Pan YX; Wu Y; Niu ZP; Jiang YW
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):608-10. PubMed ID: 19829687
[TBL] [Abstract][Full Text] [Related]
18. Leukoencephalopathy with vanishing white matter: a review.
Bugiani M; Boor I; Powers JM; Scheper GC; van der Knaap MS
J Neuropathol Exp Neurol; 2010 Oct; 69(10):987-96. PubMed ID: 20838246
[TBL] [Abstract][Full Text] [Related]
19. Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients.
Fogli A; Schiffmann R; Hugendubler L; Combes P; Bertini E; Rodriguez D; Kimball SR; Boespflug-Tanguy O
Eur J Hum Genet; 2004 Jul; 12(7):561-6. PubMed ID: 15054402
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
